statistiche ricercatore

Nome	#
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma	136
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?	108
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution	73
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?	72
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System	65
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination	39
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors	34
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies	18
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication	17
Totale	562

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	119	0	0	0	0	34	10	22	6	7	5	6	29
2021/2022	106	2	0	3	4	9	4	3	13	20	5	31	12
2022/2023	137	6	16	8	7	5	8	10	8	29	11	12	17
2023/2024	56	6	6	1	6	2	13	3	4	2	5	8	0
2024/2025	144	25	22	28	14	40	9	6	0	0	0	0	0
Totale													562

CRIS Current Research Information System